Compass Pathways reveals its timeline for psilocybin treatment’s new drug application, targeting commercial availability by 2027.

The FDA opened a 45‑day comment window on how to safely study ibogaine, seeking input on dosing, cardiac monitoring, ethics, and trial design—without touching legalization debates.

Psychedelic Alpha flagged a busy “Psychedelics Week” in DC with multiple meetings. Here’s what that activity could signal for policy, access, and the DMV community.

Four months after President Trump urged reclassification, DOJ made a partial move on cannabis scheduling. Here’s what it could mean for delivery laws and compliance.

Psychedelic Alpha reports that Resilient has resubmitted its MDMA-for-PTSD application two years after a prior rejection. Here’s what to watch, timelines, and DMV impacts.

Policy strategist Hirsh Jain joins LEEF Brands’ board as an independent director, signaling deeper focus on governance, interstate commerce, and market expansion.

A closed-door, two-day SAMHSA consultation in Washington, DC convened federal reps, researchers, regulators, and entrepreneurs to tackle psychedelic data gaps—no drug developers invited.

NORML argues federal health guidance and medical consensus point away from Schedule I. Here’s the science, policy context, and what DMV patients should watch.